Jazz Pharmaceuticals (JAZZ) director awarded 1,605 RSUs vesting in 2027

Q: What insider transaction did Jazz Pharmaceuticals (JAZZ) report for Jennifer E. Cook?

Jazz Pharmaceuticals reported that director Jennifer E. Cook received a grant of 1,605 restricted stock units , each convertible into one ordinary share. The award was made at a reported price of $0.0000 per share as equity compensation under the company’s non-employee director plan.

Q: When do Jennifer E. Cook’s new Jazz Pharmaceuticals (JAZZ) restricted stock units vest?

The restricted stock units granted to Jennifer E. Cook vest in full on July 23, 2027 . Vesting is subject to her continuous service with Jazz Pharmaceuticals and certain additional conditions specified in the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan.

Q: How many Jazz Pharmaceuticals (JAZZ) shares does Jennifer E. Cook hold after this grant?

After the reported grant, Jennifer E. Cook directly holds 12,442 ordinary shares of Jazz Pharmaceuticals. This total reflects the addition of 1,605 restricted stock units , which each represent a contingent right to receive one ordinary share upon vesting.

Q: Under which plan were Jennifer E. Cook’s Jazz (JAZZ) restricted stock units granted?

The 1,605 restricted stock units granted to Jennifer E. Cook were issued under Jazz Pharmaceuticals’ 2007 Amended and Restated Non-Employee Directors Stock Award Plan . This plan provides equity-based awards to non-employee directors as part of their overall compensation.

Q: What type of security was granted to Jennifer E. Cook by Jazz Pharmaceuticals (JAZZ)?

Jennifer E. Cook received restricted stock units , each representing a contingent right to receive one ordinary share of Jazz Pharmaceuticals upon vesting. The reported transaction lists ordinary shares, with the footnote clarifying that the award consists of restricted stock units tied to those shares.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Cook Jennifer E. reported acquisition or exercise transactions in this Form 4 filing.

Jazz Pharmaceuticals plc director Jennifer E. Cook received a grant of 1,605 restricted stock units, each representing one ordinary share, at a reported price of $0.0000 per share. Granted under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan, the units vest in full on July 23, 2027, subject to continuous service and conditions. Following this award, she directly holds 12,442 ordinary shares.

Insider Trade Summary

Net Buyer: 1,605 shares

Net Buy 1 txn

Insider Cook Jennifer E.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares ^F1	1,605	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 12,442 shares (Direct)

Footnotes (1)

F1. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027.

Key Figures

Restricted stock units granted: 1,605 units Holdings after transaction: 12,442 shares Grant date: August 5, 2026 +2 more

5 metrics

Restricted stock units granted 1,605 units Equity award to director Jennifer E. Cook

Holdings after transaction 12,442 shares Direct ordinary share holdings following the grant

Grant date August 5, 2026 Transaction date for the restricted stock unit grant

Vesting date July 23, 2027 Date on which the restricted stock units vest in full

Transaction price per share 0.0000 Reported price per ordinary share for the grant

Key Terms

restricted stock units, contingent right, continuous service, Non-Employee Directors Stock Award Plan

4 terms

restricted stock units financial

"These restricted stock units are granted pursuant to the Issuer's 2007 Amended"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each restricted stock unit represents a contingent right to receive one"

continuous service financial

"Subject to the Reporting Person's continuous service and certain additional"

Non-Employee Directors Stock Award Plan financial

"pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/07/2026 - 05:45 PM Accepted by SEC EDGAR 08/07/2026 - 05:44 PM

FAQ

What insider transaction did Jazz Pharmaceuticals (JAZZ) report for Jennifer E. Cook?

Jazz Pharmaceuticals reported that director Jennifer E. Cook received a grant of 1,605 restricted stock units, each convertible into one ordinary share. The award was made at a reported price of $0.0000 per share as equity compensation under the company’s non-employee director plan.

When do Jennifer E. Cook’s new Jazz Pharmaceuticals (JAZZ) restricted stock units vest?

The restricted stock units granted to Jennifer E. Cook vest in full on July 23, 2027. Vesting is subject to her continuous service with Jazz Pharmaceuticals and certain additional conditions specified in the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan.

How many Jazz Pharmaceuticals (JAZZ) shares does Jennifer E. Cook hold after this grant?

After the reported grant, Jennifer E. Cook directly holds 12,442 ordinary shares of Jazz Pharmaceuticals. This total reflects the addition of 1,605 restricted stock units, which each represent a contingent right to receive one ordinary share upon vesting.

Under which plan were Jennifer E. Cook’s Jazz (JAZZ) restricted stock units granted?

The 1,605 restricted stock units granted to Jennifer E. Cook were issued under Jazz Pharmaceuticals’ 2007 Amended and Restated Non-Employee Directors Stock Award Plan. This plan provides equity-based awards to non-employee directors as part of their overall compensation.

What type of security was granted to Jennifer E. Cook by Jazz Pharmaceuticals (JAZZ)?

Jennifer E. Cook received restricted stock units, each representing a contingent right to receive one ordinary share of Jazz Pharmaceuticals upon vesting. The reported transaction lists ordinary shares, with the footnote clarifying that the award consists of restricted stock units tied to those shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cook Jennifer E.

(Last)

(First)

(Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	08/05/2026		A⁽¹⁾		1,605	A	$0.0	12,442	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027.

	By: /s/Paz Dizon, as attorney in fact For: Jennifer Cook	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR